LifeMD, Inc. Q3 FY2025 earnings call

• Made progress executing strategic plan in Q3, with RexMD growth, weight management stabilization. - Substantial progress on women's health and behavioral health offerings. - Advanced development of LifeMD+ membership and in-app health marketplace. - Secured regulatory approval for nonsterile 503-A compounding pharmacy. - Successfully divested majority interest in WorkSimpli. - 2026 strategic priorities: accelerating weight management growth via collaborations, scaling women's and behavioral health, expanding and diversifying RexMD, launching unified LifeMD platform. - Announced collaborations with Novo Nordisk and Eli Lilly for reduced pricing on branded therapies. - RexMD's personalized ED medications fulfillment to shift to in-house pharmacy in early 2026. - Women's health business has exceptional advisory board and dedicated clinical team. - Psychiatry offering showing quarter-over-quarter traction. - Investing in launching core functionality and features for LifeMD platform, including website and app relaunch.

Consolidated revenue grew 13% to $60.2 million in Q3. Telehealth revenue up 18% year-over-year. RexMD business returned to growth with ~10,000 net new subscribers. Weight management offering stabilized. Adjusted EBITDA increased 30% compared to prior year. Weight management still over 50% of total revenue mix. RexMD's personalized ED medications now 25% of new ED prescriptions. Hormone replacement therapy offering showing strong momentum with expansion to 35 states. Women's and behavioral health offerings in early stages but with strong initial engagement metrics.

• Fourth quarter revenue expected in range of $45 million to $46 million, adjusted EBITDA in range of $3 million to $4 million. - Full year 2025 revenue expected in range of $192 million to $193 million, adjusted EBITDA in range of $13.5 million to $14.5 million, representing 24% revenue growth and 254% adjusted EBITDA growth vs 2024.

• Intense competition in weight management category from low-cost and low-quality compounded GLP-1 makers. - Uncertainty around regulatory environment, particularly regarding compounding. - Challenges in deploying insurance enablement in platform as planned. - Potential impact of market competition on brand uptake and revenue capture.

Q: Talk about mix of telehealth product revenue, especially weight loss, and 2026 obesity health product strategy.

A: Weight management still over 50% of revenue mix, slight sequential decline in weight loss revenue due to subscriber base flat, over half new patient sign-ups from branded therapy. 2026 driven by better pricing for branded therapies, more payer coverage, and potential FDA crackdown on compounding.

Q: Brand uptake tracking relative to expectations, impact of Novo and Lilly's other deals.

A: Expected demand for branded therapy on platform, but compounded GLP-1 world highly competitive. Oral therapies like Wegovy pill expected to be catalyst.

Q: Return to RexMD growth, ED patient acquisition outlook.

A: Most growth in RexMD from sexual health (mostly ED) and mix of HRT, hair loss, insomnia. Acquisition volume close to historical levels with healthy unit economics.

Q: Telehealth gross margin decline color.

A: Driven by shift to branded product in weight management, which doesn't carry medication processing fees, and mix of business.

Q: Insurance turn-on observations and 33% customer acquisition cost drop.

A: Demonstrates patients want to use insurance, more people going through benefits verification, leading to lower customer acquisition costs.

Q: New app impact on cross-selling.

A: Massive potential to increase cross-care sign-ups and LTV.

Q: 503-A pharmacy licensing timeline and margin impact.

A: Anticipated to be 50-state licensed in next couple of months, owning and operating it gives competitive advantage and helps drive down COGS.

Q: Oral obesity products impact on uptake.

A: Expected to be big, but difficult to put exact number, but massive demand anticipated.